MAM
Dentsu India onboards Ramsai Suriyanarayanan as managing partner – trading, media
Mumbai: Dentsu India has appointed Ramsai Suriyanarayanan as managing partner- trading, media. In his new role, Suriyanarayanan will lead media investments for Reckitt and play an integral role in developing dentsu Media’s investment model and portfolio, said the company.
Speaking on the appointment, dentsu Media South Asia CEO Divya Karani said, “We are elated to welcome Suriyanarayanan to the team. He will collaborate with our agencies and media partners to create ROI and deliver value to our clients across media in today’s dynamic media industry.”
Suriyanarayanan has over 25 years of experience, with almost 14 years at senior positions across procurement, sales and marketing functions in the media industry. In the past, he has driven many industry-first innovations across multiple clients and sectors.
Commenting on his new journey, Ramsai Suriyanarayanan stated, “It is a privilege to join this team that combines the needs of the clients with consumer intelligence insights, unlocking unique possibilities for sustainable value and lasting change. I look forward to the association and contribute to the greater objectives of dentsu and our clients.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
